Hypertensive Uveitis After Intravitreal Faricimab: Clinical and Methodological Considerations
Clinical & Experimental Ophthalmology · 2026-05 · 54 (4) · 593-594
DOI: 10.1111/ceo.70109 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical & Experimental Ophthalmology, online erschienen am 16.03.2026. Verfasst von Guanghao Qin. Beteiligte Einrichtung: Department of Clinical Research, He Eye Specialist Hospital, Shenyang, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
Autor:innen und Institutionen
- Department of Clinical Research, He Eye Specialist Hospital, Shenyang, China.
- School of Public Health, He University, Shenyang, China.
ORCID-Profile: Guanghao Qin
Zitieren
APA
Qin, G. (2026). Hypertensive Uveitis After Intravitreal Faricimab: Clinical and Methodological Considerations. Clinical & Experimental Ophthalmology, 54(4), 593-594. https://doi.org/10.1111/ceo.70109
Vancouver
Qin G. Hypertensive Uveitis After Intravitreal Faricimab: Clinical and Methodological Considerations. Clinical & Experimental Ophthalmology. 2026;54(4):593-594. doi:10.1111/ceo.70109
BibTeX
@article{Qin2026,
author = {Qin, Guanghao},
title = {Hypertensive Uveitis After Intravitreal Faricimab: Clinical and Methodological Considerations},
journal = {Clinical & Experimental Ophthalmology},
year = {2026},
volume = {54},
number = {4},
pages = {593--594},
doi = {10.1111/ceo.70109}
}
EUVIMED